دورية أكاديمية
Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel": [Annals of Oncology 28 (2017) 2768-2772]
| العنوان: | Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel": [Annals of Oncology 28 (2017) 2768-2772] |
|---|---|
| المؤلفون: | Nitz, U.A.1,2 (AUTHOR), Gluz, O.1,2,3 (AUTHOR) oleg.gluz@wsg-online.com, Christgen, M.4 (AUTHOR), Grischke, E.-M.5 (AUTHOR), Augustin, D.6 (AUTHOR), Kuemmel, S.7 (AUTHOR), Braun, M.8 (AUTHOR), Potenberg, J.9 (AUTHOR), Kohls, A.10 (AUTHOR), Krauss, K.11 (AUTHOR), Stefek, A.12 (AUTHOR), Schumacher, C.13 (AUTHOR), Forstbauer, H.14 (AUTHOR), Reimer, T.15 (AUTHOR), Fischer, H.16 (AUTHOR), Liedtke, C.17,18 (AUTHOR), Wuerstlein, R.19 (AUTHOR), Schumacher, J.20 (AUTHOR), Kates, R.1 (AUTHOR), Kreipe, H.3 (AUTHOR) |
| المصدر: | Annals of Oncology. Mar2022, Vol. 33 Issue 3, p355-355. 1p. |
| مصطلحات موضوعية: | *HER2 positive breast cancer, *TRASTUZUMAB |
| قاعدة البيانات: | Academic Search Index |
Full Text Finder | تدمد: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2021.12.008 |